Jason M Shapiro1,2, Sarah E Hagin3,4, Samir A Shah4,5, Renee Bright6, Meaghan Law6, Heather Moniz6, Julie Giacalone7, Taylor Jackvony8, Sasha Taleban4,6, Zahid Samad9, Marjorie Merrick10, Bruce E Sands7, Neal S LeLeiko8,4. 1. Division of Gastroenterology, Nutrition and Liver Diseases, Hasbro Children's Hospital/Rhode Island Hospital, 593 Eddy Street, 132 Multiphasic Building, Providence, RI, 02903, USA. jshapiro@lifespan.org. 2. The Warren Alpert School of Medicine at Brown University, Providence, RI, USA. jshapiro@lifespan.org. 3. Division of Child and Adolescent Psychiatry, the Department of Psychiatry, Hasbro Children's Hospital/Rhode Island Hospital, Providence, RI, USA. 4. The Warren Alpert School of Medicine at Brown University, Providence, RI, USA. 5. Gastroenterology Associates, Inc., Providence, RI, USA. 6. Division of Gastroenterology, Rhode Island Hospital, Providence, RI, USA. 7. Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 8. Division of Gastroenterology, Nutrition and Liver Diseases, Hasbro Children's Hospital/Rhode Island Hospital, 593 Eddy Street, 132 Multiphasic Building, Providence, RI, 02903, USA. 9. Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Atlanta, Georgia. 10. Crohn's and Colitis Foundation of America, New York, NY, USA.
Abstract
BACKGROUND: Systemic corticosteroids (CS) are a mainstay of treatment for patients with newly diagnosed inflammatory bowel disease (IBD). Previous population-based studies report CS exposure rates range from 39 to 75 % within the first year of diagnosis with surgical resection rates as high as 13-18 % in the same time frame. These reports represent an older cohort of patients enrolled over prolonged periods of time and do not necessarily reflect current treatment approaches. We examine CS use during the first year of IBD diagnosis in a community-based, inception cohort. METHODS: Data were derived from the Ocean State Crohn's and Colitis Area Registry (OSCCAR), a prospective inception cohort of IBD patients who are residents of Rhode Island. RESULTS: A total of 272 patients were included in the current analyses. Overall, 60 % of Crohn's disease and 57 % of ulcerative colitis patients were exposed to at least one course of CS during year 1 of study enrollment. Most notably, only 2 % of patients (n = 5) required a surgical resection. CONCLUSIONS: In this community-based cohort, 59 % of patients were exposed to at least one course of CS during their first year of enrollment. In contrast to previous studies, OSCCAR represents a more modern cohort of patients. While steroid exposure rates were similar or slightly higher than those in previous reports, we observed a low rate of surgical resection. As our cohort ages, future analysis will focus on the role more contemporary agents may play on the low rates of surgery we observed.
BACKGROUND: Systemic corticosteroids (CS) are a mainstay of treatment for patients with newly diagnosed inflammatory bowel disease (IBD). Previous population-based studies report CS exposure rates range from 39 to 75 % within the first year of diagnosis with surgical resection rates as high as 13-18 % in the same time frame. These reports represent an older cohort of patients enrolled over prolonged periods of time and do not necessarily reflect current treatment approaches. We examine CS use during the first year of IBD diagnosis in a community-based, inception cohort. METHODS: Data were derived from the Ocean State Crohn's and Colitis Area Registry (OSCCAR), a prospective inception cohort of IBD patients who are residents of Rhode Island. RESULTS: A total of 272 patients were included in the current analyses. Overall, 60 % of Crohn's disease and 57 % of ulcerative colitispatients were exposed to at least one course of CS during year 1 of study enrollment. Most notably, only 2 % of patients (n = 5) required a surgical resection. CONCLUSIONS: In this community-based cohort, 59 % of patients were exposed to at least one course of CS during their first year of enrollment. In contrast to previous studies, OSCCAR represents a more modern cohort of patients. While steroid exposure rates were similar or slightly higher than those in previous reports, we observed a low rate of surgical resection. As our cohort ages, future analysis will focus on the role more contemporary agents may play on the low rates of surgery we observed.
Authors: Jeanne Tung; Edward V Loftus; Deborah K Freese; Mounif El-Youssef; Alan R Zinsmeister; L Joseph Melton; W Scott Harmsen; William J Sandborn; William A Faubion Journal: Inflamm Bowel Dis Date: 2006-12 Impact factor: 5.325
Authors: Christine Rungoe; Ebbe Langholz; Mikael Andersson; Saima Basit; Nete M Nielsen; Jan Wohlfahrt; Tine Jess Journal: Gut Date: 2013-09-20 Impact factor: 23.059
Authors: Emma J Eshuis; Charlotte P Peters; Adriaan A van Bodegraven; Joep F Bartelsman; Willem Bemelman; Paul Fockens; Geert R A M D'Haens; Pieter C F Stokkers; Cyriel Y Ponsioen Journal: Inflamm Bowel Dis Date: 2013-07 Impact factor: 5.325
Authors: Laurent Peyrin-Biroulet; W Scott Harmsen; William J Tremaine; Alan R Zinsmeister; William J Sandborn; Edward V Loftus Journal: Am J Gastroenterol Date: 2012-09-04 Impact factor: 10.864
Authors: Steven F G Jeuring; Vince B C Biemans; Tim R A van den Heuvel; Maurice P Zeegers; Wim H Hameeteman; Mariëlle J L Romberg-Camps; Liekele E Oostenbrug; Ad A M Masclee; Daisy M A E Jonkers; Marieke J Pierik Journal: Am J Gastroenterol Date: 2018-01-09 Impact factor: 10.864
Authors: D Rebello; D Anjelly; D J Grand; J T Machan; M D Beland; M S Furman; J Shapiro; N LeLeiko; B E Sands; M Mallette; R Bright; H Moniz; M Merrick; S A Shah Journal: Osteoporos Int Date: 2018-03-08 Impact factor: 4.507